The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma.
Joseph M. Herman
No relevant relationships to disclose
Daniel Tandel Chang
No relevant relationships to disclose
Karyn A. Goodman
No relevant relationships to disclose
Aaron Tyler Wild
No relevant relationships to disclose
Dan Laheru
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
Luis A. Diaz
No relevant relationships to disclose
Dung Thi Le
No relevant relationships to disclose
Siva P Raman
No relevant relationships to disclose
Jeffrey P Leal
No relevant relationships to disclose
Muhammad Ali Chaudhry
No relevant relationships to disclose
Elizabeth Sugar
No relevant relationships to disclose
Laurie Ann Columbo
No relevant relationships to disclose
Ashlyn Tom
No relevant relationships to disclose
Maneesha R Limaye
No relevant relationships to disclose
Barish H Edil
No relevant relationships to disclose
Katharine Oteiza
No relevant relationships to disclose
Amy Hacker-Prietz
No relevant relationships to disclose
Christopher Lee Wolfgang
No relevant relationships to disclose
Albert Koong
No relevant relationships to disclose